We are excited to announce that we will participate in the 2025 ASCO Annual Meeting in Chicago, Illinois, from May 30 to June 3. We’ll highlight our RenMice® platforms, fully human antibody discovery services, and preclinical in vivo models driving advancements in oncology drug development. Don’t miss the opportunity to connect with our team and learn how Biocytogen is accelerating the path from discovery to clinic. Join us to network with oncology professionals from worldwide.
What is ASCO Annual Meeting?
The American Society of Clinical Oncology hosts the ASCO Annual Meeting. It is one of the largest and most prestigious gatherings in the field of oncology. The conference brings together thousands of oncology professionals from around the world to share cutting-edge research, clinical advancements, and emerging therapies in cancer care. The meeting features plenary sessions, oral abstract presentations, poster discussions, and educational panels that cover a wide range of cancer types and treatment strategies, making it a key platform for shaping the future of cancer research and patient care.
Event Overview
Date: May 30, 2025 - June 3, 2025
Venue: McCormick Place, 2301 S Martin Luther King Dr, Chicago, IL
Event Schedule
The 2025 ASCO Annual Meeting will be a 3-day event. Including guest speakers, poster presentations, etc. For more details on the conference's schedule, feel free to refer to 2025 ASCO.
About BIOCYTOGEN
Biocytogen is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA(Boston, San Francisco), and Germany (Heidelberg).
We look forward to seeing you at the 2025 ASCO in Chicago, IL!
